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Mitochondrial  disorders  are  genetic  diseases  that  result  in a deﬁciency  of  energy  metabolism  (ATP pro-
duction). A “mitochondrial  crisis”  can  occur  in  the  setting  of  infection,  dehydration,  or physiologic  stress.
The hallmark  of  a  mitochondrial  crisis  is failure  of  multiple  individual  organ  systems.  The  mortality  of
mitochondrial crisis  is  high  and  therapy  is supportive  but  involves  a speciﬁc  strategy  of hydration  with
dextrose-containing IV  ﬂuids,  avoidance  of  many  medications  known  to worsen  mitochondrial  func-
tion, and limitations  of  oxygenation  as  this  can  promote  free  radical  production.  We  report  a  case  of a
patient with  known  mitochondrial  disease  that  presented  with  a  mitochondrial  crisis  with  prominent  and
life-threatening cardiac  manifestations  including  long  QT,  ventricular  arrhythmias,  and  acute  left ventric-linical  management ular systolic  dysfunction  in  addition  to  rhabdomyolysis,  lactic  acidosis,  and  an  acute  kidney  injury.  This
patient was  managed  successfully  with  a  speciﬁcally  tailored  supportive  strategy,  a high-dose  metabolic
cocktail, permissive  hypoxia,  and  low-protein  diet.  At 10 weeks  post  discharge  all  electrocardiographic
abnormalities resolved  and  ventricular  recovery  has been  observed.  Given  the  increased  survival  of  this
population of  patients  into  adulthood  it is  important  that  these  adjunctive  therapeutic  strategies  require
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Mitochondrial disorders are increasingly encountered by adult
nd  pediatric clinicians. Adults with mitochondrial disorders usu-
lly  fall into well characterized “mitochondrial syndromes” that
re  often the result of a known mitochondrial DNA mutation. Chil-
ren with suspected mitochondrial syndromes present a greater
iagnostic  challenge as they commonly have nuclear DNA muta-
ions  and the classic signs of a mitochondrial syndrome may  be
issing  and genetic conﬁrmation is commonly elusive [1]. Reportsuggest  that the prevalence of these disorders may  exceed 1 in 5000
irths making these disorders more common than other inher-
ted  myopathies including Duchenne or myotonic myopathies [2].
DOI of original article: http://dx.doi.org/10.1016/j.jccase.2012.05.004.
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ommon to all mitochondrial disorders are deﬁciencies of energy
etabolism  and ATP production that affect cells in many organ
ystems.  A mitochondrial crisis is deﬁned by the failure of multi-
le  organ systems, commonly precipitated by a minor infection,
xposure  to medications known to interfere with respiratory chain
unction,  or other physiologic stressors. A crisis can occur over
ours  to weeks and is associated with a high mortality. Unfor-
unately,  therapeutic strategies to manage cardiac mitochondrial
risis  have not been reported.
ase  report
A  24-year-old female initially presented at the age of 5 months
ith  ketotic hypoglycemia, increased liver enzymes, and lactic
cidosis.  She was subsequently recognized to have sensorineu-
al  hearing loss, developmental delay, and short stature and was
ollowed  in the Center for Mitochondrial Disease. Genetic testing
id  not identify a known mutation. Four years prior to the cur-
ent  admission the patient was admitted for rhabdomyolysis and
f Cardiology.
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Table 1
Progression of echocardiographic changes at baseline, during the mitochondrial
crisis,  and in follow up.
DOS Baseline Day 2 Day 8 Day 120
EDD (cm) 4.7 5.1 5.1 3.8
EDS (cm) 3.1 4.0 4.2 2.9
EF (%) 64 40 28 40
RV function Normal Normal Normal Normal
MR Trace Mild Mild Trace
TR Trace Mild Trace Mild
RVSP (mm  Hg) Not done 35 Not measurable 28
EDD, end diastolic diameter; EDS, end systolic diameter; EF, ejection fraction; RV,
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ing  to cardiogenic shock, ventricular arrhythmias, murmurs, andight ventricular; MR,  mitral regurgitation; TR, tricuspid regurgitation; RVSP, right
entricular systolic pressure.
yocarditis which was treated with intravenous immunoglobulin,
nd  a seizure disorder which was treated with levetiracetam. Sev-
ral months prior to the current illness the patient was weaned
ff  her seizure medication by her neurologist, as she had remained
eizure-free for many years. The patient was well and functioning
t  her baseline attending a daycare program.
Six days prior to admission the patient was noted by the daycare
orker  to be lethargic. She was taken to a community emergency
epartment where she was found to have an elevated white blood
ell  (WBC) count to 22,000/mm3, deranged liver function tests,
nd  highly elevated creatinine kinase (CK) levels >10,000 IU/ml
onsistent  with rhabdomyolysis. She was admitted to the com-
unity  hospital where she received IV ceftriaxone and hydration.
he  was discharged when her CK levels fell below 5000 IU/ml. The
ollowing day, the patient suffered a series of tonic-clonic move-
ents  consistent with seizures and her parents brought her to
he  emergency department of the tertiary care hospital where
he  has admitted by the neurology department with a diagno-
is  of breakthrough seizures. A baseline electrocardiogram (ECG)
as  performed and showed new T-wave changes and ventric-
lar  bigeminy. The patient was moved to a pediatric cardiac
elemetry unit where she was noted to have further seizure activ-
ty.
On  physical examination, the patient was sleepy and lethargic.
he  was afebrile. She had small stature, microcephaly with low-set
ars,  and a left eye ptosis. Her cardiac exam revealed tachycar-
ia  and she had scant crackles at the bases of her lungs. She was
arm  and well perfused. Initial laboratory investigations revealed
 WBC  count of 22,000/mm3, elevated liver enzymes, and total
K  levels were 5489 IU/ml. MB  fraction was 97.9 IU/ml, troponin-T
evels  were 0.989 ng/ml, and there was lactic acidosis (lactic acid
.4  IU/ml). An echocardiogram revealed depressed left ventricular
ystolic  function (Table 1). Later that day she developed pro-
ressive  respiratory distress and bradycardia, which culminated
n  a pulseless electrical activity arrest. The patient was resusci-
ated  with cardiopulmonary resuscitation and intubated. She was
ommenced on an epinephrine drip and had further episodes of
nstable ventricular tachycardia and ventricular ﬁbrillation. She
as transferred to the adult congestive heart failure service where
epeat  echocardiogram now revealed progressively declining ven-
ricular function. The patient was commenced on IV amiodarone
ut  the QT interval was observed to be dramatically increasing
Fig.  1) and the patient had further episodes of polymorphic ven-
ricular  tachycardia. The patient was switched to an isoproterenol
nfusion. The patient became febrile and was treated with broad-
pectrum  antibiotics and suffered an acute kidney injury with her
reatinine increasing from a baseline of 0.5 to 2.3 mg/dl. On day 3
f admission the patient remained critically ill and unstable. With-
rawal  of care was discussed with the family given the worsening
linical  picture. On day 4, after discussion with the mitochondrial
s
t
iig. 1. Electrocardiographic changes at baseline, during the mitochondrial crisis,
nd in follow up after resolution of the crisis state.
isease center we  elected to commence the patient on a “mitochon-
rial  cocktail” for adjunctive treatment of mitochondrial crisis. This
onsisted of riboﬂavin 200 mg  q 12 hourly, ubiquinone 1.4 g bid,
rginine  20 g IV q 6 h for 3 days, then 15 g IV daily as continuous
nfusion, levocarnitine 1.8 g IV q 8 h, folic acid 1 mg IV bid, and thi-
mine  100 mg  IV daily. In addition to the mitochondrial cocktail
e  also treated the patient with dextrose containing IV ﬂuids, fed
he patient enterally with low-protein feeds, allowed a permissive
ypoxia,  and strictly avoided all medications known to interfere
ith  respiratory chain function. By hospital day 4 the patient’s con-
ition was  stabilizing, her ECG was normalizing, and her ejection
raction  improved (Fig. 2). The patient was extubated after 12 days
nd she was discharged home on hospital day 24 with a percu-
aneous  endoscopic gastrostomy tube for supplemental feedings
nd  for continuance of an outpatient version of the mitochondrial
ocktail that requires frequent dosing. She had home physical ther-
py for her severe de-conditioning but has since returned to her
aseline  functional status.
iscussion
Mitochondrial  disorders predominantly affect tissues depen-
ent  on aerobic metabolism including brain, retina, nerve, and
uscle  tissue. Cardiac involvement is ubiquitous in mitochon-
rial  disorders with multi-systemic involvement. Cardiomyopathy
ssociated with mitochondrial disorders, termed as ‘mitochondrial
ardiomyopathy’ is characterized by abnormal structure and/or
unction  of the heart muscle secondary to genetic defects involv-
ng  the mitochondrial respiratory chain, in the absence of other
nown  structural heart disease. Cardiac abnormalities such as left
entricular  non-compaction (LVNC) have been previously reported
n  patients with Barth syndrome [3], a mitochondrial disorder char-
cterized by X-linked cardiomyopathy, mitochondrial myopathy,
nd  cyclic neutropenia. Moreover, stressors like fever, acute illness,
eat,  or medication can precipitate an acute mitochondrial cardiac
risis,  which is characterized by multi-organ failure and elevated
actate  levels due to ATP depletion. Cardiac complications during
n  acute mitochondrial crisis can result in acute heart failure lead-udden cardiac death. Successful recovery is dependent on iden-
iﬁcation  and correction of precipitating factors. Work up should
nclude  complete blood count, liver function tests, renal function
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sig. 2. M-mode images from echocardiography performed at various time points du
eveloped  the mitochondrial crisis (no parasternal short-axis view was available fo
eft  ventricular systolic function. The ﬁnal study, performed 3 months into the patie
ests, lactate, arterial blood gas, IgG, amylase, lipase levels, ECG,
nd  echocardiogram. Since most patients have baseline acidosis
orrection  of severe acidosis should be gradual. If infection is sus-
ected,  antibiotics should be initiated. Partial pressure of O2 should
e  maintained between 50 and 60 mm Hg as excessive oxygenation
ay  worsen a crisis by increasing free radical production. The phar-
acologic  strategy includes administration of a “mitochondrial
ocktail,” which consists of respiratory chain co-factors includ-
ng  coenzyme Q10 (CoQ10), thiamine, riboﬂavin, anti-oxidants
uch  as vitamin E, agents to correct secondary biochemical deﬁcits
ncluding  l-carnitine, creatine, and folate and vasodilators such as
-arginine. There is some controversy regarding this approach as
 systematic review failed to provide clear evidence supporting
he  use of CoQ10, creatine, dichloroacetate, and dimethylglycine
n  mitochondrial disorders [4–6]. However, a partial improvement
n  clinical features using anti-oxidants including coenzyme Q10,
debenone (a coenzyme Q10 analog), vitamin E, and dihydrolipoate
as  been reported [4–6]. Patients with mitochondrial cytopathies
aking  creatine monohydrate show increased strength of high-
ntensity  anaerobic and aerobic type activities [7]. l-Arginine
nfusion improves clinical symptoms in patients with acute stroke-
ike episodes of MELAS (mitochondrial myopathy, encephalopathy,
actic  acidosis, and stroke-like episodes) [8]. Careful attention is
equired to avoid medications that can interfere with respira-
ory  chain function. These include valproic acid, statins, propofol,
minoglycosides, stretptomycin, tetracyclines, chloramphenicol,
rythromycin, azithromycin, and metformin. l-Arginine mediates
t
a
ahe course of the illness. Baseline study was  performed two years before the patient
parison). The Day 2 and Day 8 echocardiograms show progressive deterioration of
linical recovery, demonstrates improvement back to baseline.
ncorporation  of ammonia into less toxic metabolites citrulline
nd  arginosuccinate, which are easily secreted. A loading dose of
00 mg/kg of 10% l-arginine should be started through a central
ine  as it may  cause tissue necrosis and phlebitis if given peripher-
lly,  and maintained at 600 mg/kg/day. Side effects of intravenous
-arginine include hypotension, nausea, emesis, headache, and
otentially life-threatening hyperkalemia. In patients with wors-
ning  renal function, severe lactic acidosis, hyperammonemia, and
yperkalemia, hemodialysis is recommended. Patients with fever
r inability to drink or eat should be provided with dextrose
ontaining IV ﬂuids, preferably containing 10% dextrose at a main-
enance dose regardless of the levels of blood glucose. Careful
ssessment of metabolic and volume status should be done at reg-
lar  intervals. Serial echocardiography should be done at the time
f  discharge, at one month, and every three months to assess clin-
cal  recovery. In the absence of contraindications, -blockers and
ngiotensin-converting enzyme inhibitors should be considered in
ll patients with cardiomyopathy.
In  summary, successful management of mitochondrial crisis is
ased on prompt recognition of the problem, use of mitochondrial
rescue’ medications, supportive therapy aimed at treating pre-
ipitating  factors including fever, infections, avoiding medications
hat  interfere with respiratory chain function, adequate control of
eizures, good respiratory support, correction of acid base and elec-
rolyte  disturbances, providing patient and family education and
 multidisciplinary approach with dietary, physical, occupational,
nd  speech therapy.
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